UNICREDIT BANK/CALL/NOVO-NORDISK B/1600/0.1/18.06.25 | Market Closed - BOERSE MUENCHEN 01:16:16 31/05/2024 am IST | ||
| 0.24 EUR | +4.35% |
|
| Current month | -22.58% | ||
| 1 month | -22.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 30/24/30 | 0.24 | +4.35% |
| 29/24/29 | 0.23 | -4.17% |
| 28/24/28 | 0.24 | -4.00% |
| 27/24/27 | 0.25 | -3.85% |
| 24/24/24 | 0.26 | 0.00% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 01:16 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD3KEY |
| ISIN | DE000HD3KEY2 |
| Date issued | 11/03/2024 |
| Strike | 1,600 kr |
| Maturity | 18/06/2025 (384 Days) |
| Parity | 10 : 1 |
| Emission price | 0.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.6 € |
|---|---|
| Lowest since issue | 0.18 € |
| Spread | 0.3 € |
| Spread % | 78.95% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
916.9
DKK
Average target price
917.2
DKK
Spread / Average Target
+0.04%
- Stock Market
- Warrants
- Warrant
